RT Journal Article
SR Electronic
T1 Factors associated with admission of COVID-19 patients in intensive care unit
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3481
DO 10.1183/13993003.congress-2021.PA3481
VO 58
IS suppl 65
A1 Alain BAKEBE
A1 Daniel Cobarzan
A1 Kamel Chaouche
A1 Gerard Oliviero
A1 Florence Durup
A1 Sarah Benhamida
A1 Laurent Decoux
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3481.abstract
AB Background: the COVID-19 pandemic significantly impacts on the admission rate and mortality in intensive care unit (ICU) all around the world.Objective: to highlight the main determinants of admissions in ICU among hospitalized patients.Methods: a retrospective cross-sectional study was conducted during the first wave of COVID-19 pandemic in " Groupe Hospitalier du Nord Essonne", a network of three public hospital located in France. All patients who were hospitalized for COVID-19 from march 14th to may 31th 2021 were enrolled. We recorded sociodemographic data, comorbidities, comedications, time between onset of symptoms and day of admission, clinical characteristics, treatment and issue, to undertake our study. A multivariate analysis of logistic regression was performed to identify the main factors associated with admission in ICU.Results: 380 patients were included; 261 (68,7%) were male, the mean age (±SD) was 63,95±16,83 years, 23.1% were admitted in ICU. Multivariate logistic regression analysis identified male gender (OR=2.462; IC95% [1,334-4,543]; p=0,004), obesity (OR=1.836; CI95% [1.090-3.094]; p=0,022), comedication with angiotensin-receptor blocker(ARB) (OR=2.592; CI95% [1.110-5.522]; p=0,027) and Statins (OR=0.293; CI95% [0.123-0.700]; p=0.006) as main independent factors associated with admission in ICU.Conclusion: the male gender, the obesity and the comedication with ARB were main determinants of admission in ICU. So, they were associated with unfavorable clinical course of the COVID-19. However, Statins seems to be associated with good prognosis of the desease. Further studies, like randomized controlled trials will be needed to assess the real effects of Statins in SARS-CoV-2 infection.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3481.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).